Explore 3 Stock Ideas & Industry Insights Download Free Report

Canopus BioPharma Incorporated

Communication Services US CBIA

NoneUSD
0.00(0%)

Last update at 2025-05-12T13:28:52.006567Z

Day Range

--
LowHigh

52 Week Range

0.00010.17
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap0.00279M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2014-06-30 2013-06-30
Type yearly yearly
Date 2014-06-30 2013-06-30
Income before tax -0.85094M -0.52594M
Minority interest - -
Net income 1.68M -0.52594M
Selling general administrative 0.09M 0.07M
Selling and marketing expenses - -
Gross profit 0.00000M 0.00000M
Reconciled depreciation - -
Ebit -0.46530M -0.13281M
Ebitda - -
Depreciation and amortization - -
Non operating income net other - -
Operating income -0.51017M -0.11843M
Other operating expenses 0.00987M 0.00987M
Interest expense 0.00000M 0.00000M
Tax provision - -
Interest income - -
Net interest income - -
Extraordinary items - -
Non recurring - -
Other items - -
Income tax expense 0.00000M 0.00000M
Total revenue 0.00000M 0.00000M
Total operating expenses 0.00000M 0.00000M
Cost of revenue 0.00000M 0.00000M
Total other income expense net 2.58M -0.01439M
Discontinued operations - -
Net income from continuing ops 1.68M -0.52594M
Net income applicable to common shares 1.68M -0.52594M
Preferred stock and other adjustments - -
Breakdown 2014-06-30 2013-06-30
Type yearly yearly
Date 2014-06-30 2013-06-30
Total assets 1.56M 1.75M
Intangible assets 0.96M 1.32M
Earning assets - -
Other current assets - -
Total liab 2.11M 4.39M
Total stockholder equity -0.54270M -2.63644M
Deferred long term liab - -
Other current liab -0.09365M -0.00508M
Common stock 0.31M 0.27M
Capital stock - -
Retained earnings -11.04498M -10.19404M
Other liab - -
Good will - -
Other assets 0.57M 0.43M
Cash 0.03M 0.00010M
Cash and equivalents - -
Total current liabilities 2.11M 4.39M
Current deferred revenue - -
Net debt - -
Short term debt 1.94M 4.06M
Short long term debt 1.94M 4.06M
Short long term debt total - -
Other stockholder equity 2.54M -
Property plant equipment - -
Total current assets 0.03M 0.00010M
Long term investments - -
Net tangible assets -1.50338M -3.95949M
Short term investments - -
Net receivables - -
Long term debt - -
Inventory - -
Accounts payable 0.26M 0.33M
Total permanent equity - -
Noncontrolling interest in consolidated entity - -
Temporary equity redeemable noncontrolling interests - -
Accumulated other comprehensive income - -
Additional paid in capital - -
Common stock total equity - -
Preferred stock total equity - -
Retained earnings total equity - -
Treasury stock - -
Accumulated amortization - -
Non currrent assets other - -
Deferred long term asset charges - -
Non current assets total - -
Capital lease obligations - -
Long term debt total - -
Breakdown 2014-06-30 2013-06-30
Type yearly yearly
Date 2014-06-30 2013-06-30
Investments -0.14487M -0.42887M
Change to liabilities -0.07424M -0.01235M
Total cashflows from investing activities -2.35333M 0.45M
Net borrowings - -
Total cash from financing activities 0.41M 0.08M
Change to operating activities - -
Net income 1.68M -0.52594M
Change in cash 0.03M -0.00037M
Begin period cash flow - -
End period cash flow - -
Total cash from operating activities 1.98M -0.52841M
Issuance of capital stock - -
Depreciation 0.00987M 0.00987M
Other cashflows from investing activities -2.20846M 0.88M
Dividends paid - -
Change to inventory - -
Change to account receivables - -
Sale purchase of stock 0.41M 0.08M
Other cashflows from financing activities - -
Change to netincome 0.35M 0.35M
Capital expenditures 0.00000M 0.00000M
Change receivables - -
Cash flows other operating - -
Exchange rate changes - -
Cash and cash equivalents changes - -
Change in working capital - -
Stock based compensation - -
Other non cash items - -
Free cash flow - -

Peer Comparison

Sector: Communication Services Industry: Advertising Agencies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
CBIA
Canopus BioPharma Incorporated
- -% - - - - -
APP
Applovin Corp
-0.32 0.07% 469.39 49.00 31.75 30.27 77.57 30.41 38.27
PGPEF
Publicis Groupe S.A
- -% 103.00 15.93 11.57 1.55 2.24 1.76 9.39
PUBGY
Publicis Groupe SA
-0.52 2.03% 25.04 16.35 11.74 1.57 2.27 1.76 9.39
OMC
Omnicom Group Inc
1.20 1.68% 72.55 12.68 11.89 1.17 5.11 1.58 9.50

Reports Covered

Stock Research & News

Profile

Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007. Canopus BioPharma Incorporated is based in Santa Monica, California.

Canopus BioPharma Incorporated

233 Wilshire Boulevard, Santa Monica, CA, United States, 90401

  • 353-627-8674

Key Executives

Name Title Year Born
Mr. Patrick T. Prendergast Chairman & CEO NA
Mr. Leo J. Prendergast COO & Director NA
Mr. Andries J. Lategan B.Pharm, M.Sc, Ph.D. Chief Scientific Officer NA
Ms. Elizabeth Shanahan B.Sc. (Hon) Pres of Oncology Division NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.